Institute of Integrated Traditional Chinese and Western Medicine, Beijing University of Chinese Medicine, Beijing, 100029, China.
Institute of Metabolic Diseases, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, 100053, China.
Syst Rev. 2024 Sep 19;13(1):238. doi: 10.1186/s13643-024-02656-4.
Arecae Semen is a traditional herbal medicine widely used in the medical service and food industry, but in recent years, the carcinogenesis of edible Arecae Semen chewing has aroused comprehensive attention, therefore it is necessary to evaluate its medicinal properties. Increasing evidence has shown that Arecae Semen Compounds (ASC) possess antidepressant ability. This study aimed to evaluate the effectiveness and safety of ASC in the treatment of depression.
We retrieved articles in eight databases from their inception to May 2024. Randomized controlled trials (RCTs) comparing the effects of ASC alone or combined with routine treatment in patients with depression were identified. The Cochrane risk of bias (ROB) tool (ROB 2) was used for assessing the ROB in the included trials. Grading of Recommendations Assessment, Development, and Evaluation (GRADE) was used to assess the certainty of the evidence for the review outcomes. The outcomes included Hamilton depression rating scale (HAMD) scores, depression-related symptoms, serum dopamine levels, and adverse events. Stata 14.0 was used for data analysis calculating standardized mean difference (SMD) for continuous outcomes and relative risk (RR) for binary outcomes, both with 95% confidence intervals (CI).
Nine RCTs involving 787 patients were included in this review. ASC lowered HAMD scores (SMD - 3.43, 95% CI - 5.24 to - 1.61; I = 95.2%, P < 0.001), alleviated depression-related symptoms, increased serum dopamine levels, and reduced the incidence of adverse events slightly (RR 0.18, 95% CI 0.04 to 0.77; I = 0, P = 0.775) compared with the control group. Publication bias might account for the asymmetrical presentation of funnel plots. Meta-regression analysis revealed that regarding HAMD scores, there was no significant relationship with duration, sample size, or treatment strategy. The evidence of the outcomes was of very low certainty.
ASC may achieve better therapeutic effects, alleviate depression-related symptoms with a lower incidence of adverse events, and provide a potentially effective and safe complementary therapy for patients with depression. However, the evidence is very uncertain so further researches are required to validate our results and explore clinical implications of Arecae Semen in depth.
PROSPERO CRD42022361150.
槟榔是一种传统的中草药,广泛应用于医疗服务和食品工业,但近年来,食用槟榔的致癌性引起了广泛关注,因此有必要对其药用性能进行评估。越来越多的证据表明,槟榔复方(ASC)具有抗抑郁作用。本研究旨在评估 ASC 单独或联合常规治疗抑郁症患者的有效性和安全性。
我们从建库起至 2024 年 5 月检索了八个数据库中的文章。确定了比较 ASC 单独或联合常规治疗抑郁症患者的效果的随机对照试验(RCT)。使用 Cochrane 偏倚风险(ROB)工具(ROB 2)评估纳入试验的 ROB。使用推荐评估、制定与评价分级(GRADE)评估评价结果的证据确定性。结局包括汉密尔顿抑郁评定量表(HAMD)评分、抑郁相关症状、血清多巴胺水平和不良事件。使用 Stata 14.0 计算连续结局的标准化均数差(SMD)和二分类结局的相对风险(RR),均采用 95%置信区间(CI)。
本综述纳入了 9 项 RCT,共 787 名患者。ASC 降低了 HAMD 评分(SMD-3.43,95%CI-5.24 至-1.61;I=95.2%,P<0.001),缓解了抑郁相关症状,增加了血清多巴胺水平,且略微降低了不良事件的发生率(RR 0.18,95%CI 0.04 至 0.77;I=0,P=0.775),与对照组相比。漏斗图的不对称表现可能表明存在发表偏倚。Meta 回归分析表明,HAMD 评分与持续时间、样本量或治疗策略之间没有显著关系。结局的证据确定性非常低。
ASC 可能对抑郁症患者产生更好的治疗效果,缓解抑郁相关症状,且不良事件发生率较低,为抑郁症患者提供了一种潜在有效的安全补充治疗方法。然而,证据非常不确定,因此需要进一步的研究来验证我们的结果,并深入探讨槟榔的临床意义。
PROSPERO CRD42022361150。